BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 19375924)

  • 41. Study on the compounds containing 19F and 10B atoms in a single molecule for the application to MRI and BNCT.
    Hattori Y; Asano T; Niki Y; Kondoh H; Kirihata M; Yamaguchi Y; Wakamiya T
    Bioorg Med Chem; 2006 May; 14(10):3258-62. PubMed ID: 16460951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).
    Henriksson R; Capala J; Michanek A; Lindahl SA; Salford LG; Franzén L; Blomquist E; Westlin JE; Bergenheim AT;
    Radiother Oncol; 2008 Aug; 88(2):183-91. PubMed ID: 18336940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biodistribution of phenylboric acid derivative entrapped lipiodol and 4-borono-2-18F-fluoro-L-phenylalanine-fructose in GP7TB liver tumor bearing rats for BNCT.
    Liao AH; Chou FI; Kuo YC; Chen HW; Kai JJ; Chang CW; Chen FD; Hwang JJ
    Appl Radiat Isot; 2010 Mar; 68(3):422-6. PubMed ID: 20056428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT.
    Menichetti L; Cionini L; Sauerwein WA; Altieri S; Solin O; Minn H; Salvadori PA
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S351-4. PubMed ID: 19410471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biodistribution of GB-10 (Na(2)(10)B10H10 compound for boron neutron capture therapy (BNCT) in an experimental model of oral cancer in the hamster cheek pouch.
    Heber E; Trivillin VA; Nigg D; Kreimann EL; Itoiz ME; Rebagliati RJ; Batistoni D; Schwint AE
    Arch Oral Biol; 2004 Apr; 49(4):313-24. PubMed ID: 15003550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET.
    Havu-Aurén K; Kiiski J; Lehtiö K; Eskola O; Kulvik M; Vuorinen V; Oikonen V; Vähätalo J; Jääskeläinen J; Minn H
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):87-94. PubMed ID: 16896669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning.
    Kabalka GW; Smith GT; Dyke JP; Reid WS; Longford CP; Roberts TG; Reddy NK; Buonocore E; Hübner KF
    J Nucl Med; 1997 Nov; 38(11):1762-7. PubMed ID: 9374349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Boron biodistribution study in colorectal liver metastases patients in Argentina.
    Cardoso J; Nievas S; Pereira M; Schwint A; Trivillin V; Pozzi E; Heber E; Monti Hughes A; Sanchez P; Bumaschny E; Itoiz M; Liberman S
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S76-9. PubMed ID: 19375931
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improvement of the tumor-suppressive effect of boron neutron capture therapy for amelanotic melanoma by intratumoral injection of the tyrosinase gene.
    Morita N; Hiratsuka J; Kondoh H; Uno M; Asano T; Niki Y; Sakurai Y; Ono K; Harada T; Imajo Y
    Cancer Res; 2006 Apr; 66(7):3747-53. PubMed ID: 16585201
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Boron neutron capture therapy for undifferentiated thyroid carcinoma: preliminary results with the combined use of BPA and BOPP.
    Viaggi M; Dagrosa MA; Longhino J; Blaumann H; Calzetta O; Kahl SB; Juvenal GJ; Pisarev MA
    Appl Radiat Isot; 2004 Nov; 61(5):905-9. PubMed ID: 15308166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and in vivo biodistribution of BPA-Gd-DTPA complex as a potential MRI contrast carrier for neutron capture therapy.
    Takahashi K; Nakamura H; Furumoto S; Yamamoto K; Fukuda H; Matsumura A; Yamamoto Y
    Bioorg Med Chem; 2005 Feb; 13(3):735-43. PubMed ID: 15653341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Homogeneous boron targeting of heterogeneous tumors for boron neutron capture therapy (BNCT): chemical analyses in the hamster cheek pouch oral cancer model.
    Heber EM; Trivillin VA; Nigg DW; Itoiz ME; Gonzalez BN; Rebagliati RJ; Batistoni D; Kreimann EL; Schwint AE
    Arch Oral Biol; 2006 Oct; 51(10):922-9. PubMed ID: 16696934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early effect of boron neutron capture therapy mediated by boronophenylalanine (BPA-BNCT) on mast cells in premalignant tissue and tumors of the hamster cheek pouch.
    Aromando RF; Trivillin VA; Heber EM; Pozzi E; Schwint AE; Itoiz ME
    Oral Oncol; 2010 May; 46(5):355-9. PubMed ID: 20308008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Boron neutron capture therapy at the crossroads: challenges and opportunities.
    Barth RF
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S3-6. PubMed ID: 19467879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity.
    Coderre JA; Chanana AD; Joel DD; Elowitz EH; Micca PL; Nawrocky MM; Chadha M; Gebbers JO; Shady M; Peress NS; Slatkin DN
    Radiat Res; 1998 Feb; 149(2):163-70. PubMed ID: 9457896
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term infusions of p-boronophenylalanine for boron neutron capture therapy: evaluation using rat brain tumor and spinal cord models.
    Morris GM; Micca PL; Nawrocky MM; Weissfloch LE; Coderre JA
    Radiat Res; 2002 Dec; 158(6):743-52. PubMed ID: 12452777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vivo evaluation of phosphorous-containing derivatives of dodecahydro-closo-dodecaborate for boron neutron capture therapy of gliomas and sarcomas.
    Tjarks W; Barth RF; Rotaru JH; Adams DM; Yang W; Kultyshev RG; Forrester J; Barnum BA; Soloway AH; Shore SG
    Anticancer Res; 2001; 21(2A):841-6. PubMed ID: 11396173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC): application for photodynamic therapy and boron neutron capture therapy.
    Hiramatsu R; Kawabata S; Tanaka H; Sakurai Y; Suzuki M; Ono K; Miyatake S; Kuroiwa T; Hao E; Vicente MG
    J Pharm Sci; 2015 Mar; 104(3):962-70. PubMed ID: 25546823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proton nuclear magnetic resonance measurement of p-boronophenylalanine (BPA): a therapeutic agent for boron neutron capture therapy.
    Zuo CS; Prasad PV; Busse P; Tang L; Zamenhof RG
    Med Phys; 1999 Jul; 26(7):1230-6. PubMed ID: 10435522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective uptake of p-borophenylalanine by undifferentiated thyroid carcinoma for boron neutron capture therapy.
    Dagrosa MA; Viaggi M; Kreimann E; Farías S; Garavaglia R; Agote M; Cabrini RL; Dadino JL; Juvenal GJ; Pisarev MA
    Thyroid; 2002 Jan; 12(1):7-12. PubMed ID: 11838734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.